[1]王镜纯,吴 宝,白玉勤.肺腺癌组织细胞分裂周期相关蛋白8蛋白表达及与临床病理参数、预后关系分析[J].陕西医学杂志,2023,52(10):1427-1430.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.033]
　WANG Jingchun,WU Bao,BAI Yuqin.Expression of CDCA8 protein in lung adenocarcinoma tissue and its relationship with clinicopathologic parameters and the prognosis[J].,2023,52(10):1427-1430.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.033]
点击复制

肺腺癌组织细胞分裂周期相关蛋白8蛋白表达及与临床病理参数、预后关系分析
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年10期
页码:
1427-1430
栏目:
临床病理
出版日期:
2023-10-05

文章信息/Info

Title:
Expression of CDCA8 protein in lung adenocarcinoma tissue and its relationship with clinicopathologic parameters and the prognosis
作者:
王镜纯1; 2; 吴 宝3; 白玉勤4
(1.锦州医科大学赤峰学院培养基地,内蒙古 赤峰 024005; 2.赤峰市医院肿瘤内科,内蒙古 赤峰 024009; 3.赤峰学院中医蒙医学院,内蒙古 赤峰 024005; 4.赤峰市肿瘤医院病理科,内蒙古 赤峰 024009)
Author(s):
WANG Jingchun; WU Bao; BAI Yuqin
(Cultivation Base of Chifeng College of Jinzhou Medical University,Chifeng 024005,China)
关键词:
腺癌;  细胞分裂周期相关蛋白8;  蛋白表达;  病理参数;  预后;  生存分析
Keywords:
Lung adenocarcinoma;  Cell division cycle associated 8;  Protein expression;  Pathological parameter;  Prognosis;  Survival analysis
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2023.10.033
文献标志码:
A
摘要:
目的:分析肺腺癌(LUAD)组织细胞分裂周期相关蛋白8(CDCA8)蛋白表达水平,并探究CDCA8蛋白表达与临床病理参数、预后的关系。方法:选择98例LUAD患者,按照CDCA8蛋白表达水平分为高阳性组(67例)和低阳性组(31例)。收集并比较两组临床病理参数,并通过生存曲线来比较两组LUAD患者无病生存率和总生存率。结果:以CDCA8蛋白表达为因浓度变量,并以TNM分期、肿瘤体积、淋巴结转移、脏层胸膜侵犯为协变量,Logistics回归分析结果显示肿瘤体积(10～30 mm2、>30 mm2)、淋巴结转移是CDCA8蛋白高阳性表达的影响因素(P<0.05)。CDCA8蛋白高阳性组无病生存率、总生存率为28.5%、60.9%,低于低阳性组的51.6%、80.0%(均P<0.05)。结论:LUAD组织CDCA8(1:500稀释)蛋白表达与临床病理参数、预后存在直接关联,检测CDCA8(1:500稀释)蛋白表达水平可以帮助临床医生判断LUAD患者病情进展和预后,利于指导治疗方案制定。
Abstract:
Objective:To analyze the expression level of cell division cycle associated 8(CDCA8)protein in lung adenocarcinoma(LUAD)tissue,and investigate the relationship between CDCA8 protein expression and clinicopathological parameters and the prognosis.Methods:A total of 98 patients with LUAD who were divided into the highly positive group(67 cases)and the low positive group(31 cases)according to the expression level of CDCA8 protein.The clinicopathological parameters of the two groups were collected and compared,and the disease-free survival rate and overall survival rate of the two groups of LUAD patients were compared by survival curve.Results:With CDCA8 protein expression as the dependent variable and TNM stage,tumor volume,lymph node metastasis and visceral pleural invasion as the covariates,logistic regression analysis results showed that tumor volume(10-30 mm2,>30 mm2)and lymph node metastasis were influencing factors of high expression of CDCA8 protein(all P<0.05).The disease-free survival rate and total survival rate in the highly positive group(28.5% and 60.9%)were lower than those in the low positive group(51.6% vs.80.0%)(all P<0.05).Conclusion:The expression of CDCA8 protein in LUAD tissue is directly related to clinicopathological parameters and the prognosis.Detecting CDCA8 protein expression level can help clinicians judge the progression and prognosis of LUAD and guide the formulation of treatment plans.

参考文献/References:

[1] 刘 琳,焦宗林,曾 媛,等.浸润性肺腺癌不同病理亚型的研究进展[J].癌症进展,2020,18(5):436-438,466.
[2] 韩 乐,陈文娟,张一力.肺腺癌392例临床病理特征与骨转移相关性分析[J].陕西医学杂志,2020,49(12):1688-1690.
[3] 张 驰,史清明,顾康生.靶向+化疗治疗EGFR+TP53共变的老年肺腺癌患者的临床疗效及安全性[J].中国老年学杂志,2022,42(8):1830-1832.
[4] Chu X,Qiang H,Xie M,et al.Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors:A multicenter retrospective study[J].Cancer Immunol Immunother,2022,71(7):1625-1631.
[5] Olmedo ME,Cervera R,Cabezon-Gutierrez L,et al.New horizons for uncommon mutations in non-small cell lung cancer:BRAF,KRAS,RET,MET,NTRK,HER2[J].World J Clin Oncol,2022,13(4):276-286.
[6] 李博文,张心宇,刘 洋,等.肺腺癌患者血清长链非编码RNA miR155HG表达及意义[J].陕西医学杂志,2022,51(4):492-496.
[7] 王 徽,白玉勤.肺腺癌移植瘤裸鼠模型侵袭组织中酪氨酸蛋白激酶受体A7、表皮生长因子受体和Ki67蛋白表达及意义[J].陕西医学杂志,2021,50(9):1060-1063.
[8] 李成长,徐久成.具有预后价值的肺腺癌发病关键基因鉴别[J].中国老年学杂志,2021,41(1):36-41.
[9] 中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2019版)[J].中华肿瘤杂志,2020,42(4):257-287.
[10] 谢雯莹,贺 洋,傅 晓,等.肺腺癌相关组织学特征与PD-L1表达EGFR基因突变类型的关系[J].中国肿瘤临床,2022,49(15):769-774.
[11] 梁 宇,侯和磊,姜 曼,等.中国年轻肺腺癌患者基因特点研究[J].中国肺癌杂志,2020,23(4):239-246.
[12] 屈 直,王 芬,李志明,等.二陈汤对Lewis肺癌移植瘤生长及Hedgehog通路蛋白表达的影响[J].陕西中医,2022,43(5):555-558,563.
[13] Xiang C,Sun WH,Ke Y,et al.CDCA8 contributes to the development and progression of thyroid cancer through regulating CDK1[J].J Cancer,2022,13(7):2322-2335.
[14] Guo R,Ying J,Jia L,et al.Regulators CDCA8 as potential targets and biomarkers for the prognosis of human skin cutaneous melanoma[J].J Cosmet Dermatol,2022,21(11):6034-6048.
[15] Wan S,He Y,Zhang B,et al.Overexpression of CDCA8 predicts poor prognosis and promotes tumor cell growth in prostate cancer[J].Front Oncol,2022,12(4):1-13.
[16] Hu C,Wu J,Wang L,et al.MiR-133b inhibits cell proliferation,migration,and invasion of lung adenocarcinoma by targeting CDCA8[J].Pathol Res Pract,2021,223(7):153459.
[17] 李紫荆,刘晓红,覃志翔,等.细胞分裂周期蛋白8对肿瘤预后和肿瘤免疫的影响[J].中华实验外科杂志,2022,39(5):953-957.
[18] 魏永健,胡进静,李 汛.CDCA8与肿瘤发生发展及干细胞干性维持的关系[J].国际肿瘤学杂志,2021,48(4):216-219.
[19] Li B,Liu B,Zhang X,et al.KIF18B promotes the proliferation of pancreatic ductal adenocarcinoma via activating the expression of CDCA8[J].J Cell Physiol,2020,235(5):4227-4238.
[20] Bu Y,Shi L,Yu D,et al.CDCA8 is a key mediator of estrogen-stimulated cell proliferation in breast cancer cells[J].Gene,2019,703(6):1-6.
[21] 徐雷棣,车映刚,常 宁,等.肿瘤干性基因CDCA8对肺腺癌患者预后影响[J].国际呼吸杂志,2021,41(23):1774-1782.

相似文献/References:

[1]史 璇,张 鑫,朱金朋,等.结直肠腺癌组织中CYR61和血管内皮生长因子的表达及相关性研究*[J].陕西医学杂志,2019,(4):421.
　SHI Xuan,ZHANG Xin,ZHU Jinpeng,et al.Expressions and relationship of CYR61 and VEGF in colorectal adenocarcinoma[J].,2019,(10):421.
[2]胡乃军,王海龙.胃腺癌组织中MMP11、MMP12和VEGFD的表达及临床意义[J].陕西医学杂志,2019,(5):554.
[3]裴彦江,戚 斌.术前替吉奥联合奥沙利铂新辅助化疗治疗SiewertⅡ型食管胃结合部腺癌临床疗效研究[J].陕西医学杂志,2022,51(11):1420.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.024]

备注/Memo

备注/Memo:
基金项目:内蒙古自治区教育厅科学研究项目(NJZY22178)
更新日期/Last Update: 2023-10-07